Cargando…
In Vivo Antiviral Activity of Baloxavir against PA/I38T-Substituted Influenza A Viruses at Clinically Relevant Doses
Although the prevalence of polymerase acidic (PA)/I38T strains of influenza virus with reduced susceptibility to baloxavir acid is low, there is a possibility of emergence under selective pressure. Furthermore, the virus may be transmitted between humans. We investigated the in vivo efficacy of balo...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10222987/ https://www.ncbi.nlm.nih.gov/pubmed/37243240 http://dx.doi.org/10.3390/v15051154 |
_version_ | 1785049831806337024 |
---|---|
author | Kuroda, Takayuki Fukao, Keita Yoshida, Shinpei Oka, Ryoko Baba, Kaoru Ando, Yoshinori Taniguchi, Keiichi Noshi, Takeshi Shishido, Takao |
author_facet | Kuroda, Takayuki Fukao, Keita Yoshida, Shinpei Oka, Ryoko Baba, Kaoru Ando, Yoshinori Taniguchi, Keiichi Noshi, Takeshi Shishido, Takao |
author_sort | Kuroda, Takayuki |
collection | PubMed |
description | Although the prevalence of polymerase acidic (PA)/I38T strains of influenza virus with reduced susceptibility to baloxavir acid is low, there is a possibility of emergence under selective pressure. Furthermore, the virus may be transmitted between humans. We investigated the in vivo efficacy of baloxavir acid and oseltamivir phosphate against influenza A subtypes H1N1, H1N1pdm09, and H3N2, with PA/I38T substitution, at doses simulating human plasma concentrations. A pharmacokinetic/pharmacodynamic analysis was performed to strengthen the validity of the findings and the applicability in a clinical setting. Although the antiviral effect of baloxavir acid was attenuated in mice infected with PA/I38T-substituted viral strains compared with the wild type (WT), baloxavir acid significantly reduced virus titers at higher—but clinically relevant—doses. The virus titer reduction with baloxavir acid (30 mg/kg subcutaneous single dose) was comparable to that of oseltamivir phosphate (5 mg/kg orally twice daily) against H1N1 and H1N1pdm09 PA/I38T strains in mice, as well as the H3N2 PA/I38T strain in hamsters. Baloxavir acid demonstrated an antiviral effect against PA/I38T-substituted strains, at day 6, with no further viral rebound. In conclusion, baloxavir acid demonstrated dose-dependent antiviral effects comparable to that of oseltamivir phosphate, even though the degree of lung virus titer reduction was diminished in animal models infected with PA/I38T-substituted strains. |
format | Online Article Text |
id | pubmed-10222987 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102229872023-05-28 In Vivo Antiviral Activity of Baloxavir against PA/I38T-Substituted Influenza A Viruses at Clinically Relevant Doses Kuroda, Takayuki Fukao, Keita Yoshida, Shinpei Oka, Ryoko Baba, Kaoru Ando, Yoshinori Taniguchi, Keiichi Noshi, Takeshi Shishido, Takao Viruses Article Although the prevalence of polymerase acidic (PA)/I38T strains of influenza virus with reduced susceptibility to baloxavir acid is low, there is a possibility of emergence under selective pressure. Furthermore, the virus may be transmitted between humans. We investigated the in vivo efficacy of baloxavir acid and oseltamivir phosphate against influenza A subtypes H1N1, H1N1pdm09, and H3N2, with PA/I38T substitution, at doses simulating human plasma concentrations. A pharmacokinetic/pharmacodynamic analysis was performed to strengthen the validity of the findings and the applicability in a clinical setting. Although the antiviral effect of baloxavir acid was attenuated in mice infected with PA/I38T-substituted viral strains compared with the wild type (WT), baloxavir acid significantly reduced virus titers at higher—but clinically relevant—doses. The virus titer reduction with baloxavir acid (30 mg/kg subcutaneous single dose) was comparable to that of oseltamivir phosphate (5 mg/kg orally twice daily) against H1N1 and H1N1pdm09 PA/I38T strains in mice, as well as the H3N2 PA/I38T strain in hamsters. Baloxavir acid demonstrated an antiviral effect against PA/I38T-substituted strains, at day 6, with no further viral rebound. In conclusion, baloxavir acid demonstrated dose-dependent antiviral effects comparable to that of oseltamivir phosphate, even though the degree of lung virus titer reduction was diminished in animal models infected with PA/I38T-substituted strains. MDPI 2023-05-11 /pmc/articles/PMC10222987/ /pubmed/37243240 http://dx.doi.org/10.3390/v15051154 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kuroda, Takayuki Fukao, Keita Yoshida, Shinpei Oka, Ryoko Baba, Kaoru Ando, Yoshinori Taniguchi, Keiichi Noshi, Takeshi Shishido, Takao In Vivo Antiviral Activity of Baloxavir against PA/I38T-Substituted Influenza A Viruses at Clinically Relevant Doses |
title | In Vivo Antiviral Activity of Baloxavir against PA/I38T-Substituted Influenza A Viruses at Clinically Relevant Doses |
title_full | In Vivo Antiviral Activity of Baloxavir against PA/I38T-Substituted Influenza A Viruses at Clinically Relevant Doses |
title_fullStr | In Vivo Antiviral Activity of Baloxavir against PA/I38T-Substituted Influenza A Viruses at Clinically Relevant Doses |
title_full_unstemmed | In Vivo Antiviral Activity of Baloxavir against PA/I38T-Substituted Influenza A Viruses at Clinically Relevant Doses |
title_short | In Vivo Antiviral Activity of Baloxavir against PA/I38T-Substituted Influenza A Viruses at Clinically Relevant Doses |
title_sort | in vivo antiviral activity of baloxavir against pa/i38t-substituted influenza a viruses at clinically relevant doses |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10222987/ https://www.ncbi.nlm.nih.gov/pubmed/37243240 http://dx.doi.org/10.3390/v15051154 |
work_keys_str_mv | AT kurodatakayuki invivoantiviralactivityofbaloxaviragainstpai38tsubstitutedinfluenzaavirusesatclinicallyrelevantdoses AT fukaokeita invivoantiviralactivityofbaloxaviragainstpai38tsubstitutedinfluenzaavirusesatclinicallyrelevantdoses AT yoshidashinpei invivoantiviralactivityofbaloxaviragainstpai38tsubstitutedinfluenzaavirusesatclinicallyrelevantdoses AT okaryoko invivoantiviralactivityofbaloxaviragainstpai38tsubstitutedinfluenzaavirusesatclinicallyrelevantdoses AT babakaoru invivoantiviralactivityofbaloxaviragainstpai38tsubstitutedinfluenzaavirusesatclinicallyrelevantdoses AT andoyoshinori invivoantiviralactivityofbaloxaviragainstpai38tsubstitutedinfluenzaavirusesatclinicallyrelevantdoses AT taniguchikeiichi invivoantiviralactivityofbaloxaviragainstpai38tsubstitutedinfluenzaavirusesatclinicallyrelevantdoses AT noshitakeshi invivoantiviralactivityofbaloxaviragainstpai38tsubstitutedinfluenzaavirusesatclinicallyrelevantdoses AT shishidotakao invivoantiviralactivityofbaloxaviragainstpai38tsubstitutedinfluenzaavirusesatclinicallyrelevantdoses |